In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: Identification of stimulating factors for in vivo glycosylation

Microbial Cell Factories

Volumn 14, Issue 1, 2015, Pages

  Kämpf, Michael M ^a,b   Braun, Martin ^b   Sirena, Dominique ^b   Ihssen, Julian ^a   Thöny Meyer, Linda ^a   Ren, Qun ^a  

^a SWISS FEDERAL LABORATORIES FOR MATERIALS SCIENCE AND TECHNOLOGY   (Switzerland)

^b GlycoVaxyn AG   (Switzerland)

Author keywords

Glycoconjugate vaccine; High cell density culture; Process optimization; Recombinant E. coli; Shigella flexneri 2a

Indexed keywords

BACTERIAL ENZYME; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; CARBOHYDRATE DERIVATIVE; CARRIER PROTEIN; EXOTOXIN; EXOTOXIN A PROTEIN; FACTOR A; GLYCAN DERIVATIVE; GLYCOCONJUGATE; MAGNESIUM ION; MONOSACCHARIDE; N ACETYLGLUCOSAMINE; N GLYCAN; O POLYSACCHARIDE; OLIGOSACCHARYLTRANSFERASE PGLB; RECOMBINANT GLYCOCONJUGATE VACCINE; RECOMBINANT VACCINE; SHIGELLA VACCINE; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; CAMPYLOBACTER JEJUNI; CELL DENSITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG IDENTIFICATION; ESCHERICHIA COLI; FED BATCH FERMENTATION; FERMENTATION OPTIMIZATION; GLUCOSE TRANSPORT; GLYCOPROTEIN SYNTHESIS; GLYCOSYLATION; IN VIVO STUDY; NONHUMAN; PROTEIN GLYCOSYLATION; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; SEROTYPE; SHIGELLA FLEXNERI; SHIGELLOSIS; VACCINE PRODUCTION; BIOMASS; BIOREACTOR; DRUG EFFECTS; DYSENTERY, BACILLARY; FERMENTATION; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; KINETICS; METABOLISM; MICROBIOLOGY; PROCEDURES; PROTEIN ENGINEERING; REPRODUCIBILITY; TIME FACTOR; WESTERN BLOTTING;

BACTERIA (MICROORGANISMS); CAMPYLOBACTER JEJUNI; ESCHERICHIA COLI; PROKARYOTA; PSEUDOMONAS AERUGINOSA; PUFFINUS AURICULARIS; SHIGELLA FLEXNERI 2A;

ACETYLGLUCOSAMINE; BIOMASS; BIOREACTORS; BLOTTING, WESTERN; CAMPYLOBACTER JEJUNI; DYSENTERY, BACILLARY; ESCHERICHIA COLI; FERMENTATION; GENE EXPRESSION; GLYCOCONJUGATES; GLYCOSYLATION; HUMANS; KINETICS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SHIGELLA FLEXNERI; SHIGELLA VACCINES; TIME FACTORS;

EID: 84924113151     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/s12934-015-0195-7     Document Type: Article

References (66)

1. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ. 1999;77(8):651-66.
2. Niyogi SK. Shigellosis. J Microbiol. 2005;43(2):133-43.
3. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol. 2007;5(7):540-53.
4. Ranallo RT, Fonseka S, Boren TL, Bedford LA, Kaminski RW, Thakkar S, et al. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates. Vaccine. 2012;30(34):5159-71.
5. Barman S, Koley H, Ramamurthy T, Chakrabarti MK, Shinoda S, Nair GB, et al. Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model. Microbiol Immunol. 2013;57(11):762-71.
6. Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, et al. Characterization of a novel fusion protein of IpaB and IpaD of Shigella and its potential as a pan-Shigella vaccine. Infect Immun. 2013;81(12):4470-7.
7. Pore D, Mahata N, Pal A, Chakrabarti MK. Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model. PLoS One. 2011;6(7):e22663.
8. Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, et al. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine. 2011;29(40):7009-19.
9. Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Belot F, Cohen D, et al. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J Immunol. 2009;182(4):2241-7.
10. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res. 2003;338:2539-47.
11. Avci FY, Kasper DL. How Bacterial Carbohydrates Influence the Adaptive Immune System. Annu Rev Immunol. 2010;28:107-30.
12. Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, et al. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun. 1996;64(10):4074-7.
13. Frasch CE. Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges. Vaccine. 2009;27(46):6468-70.
14. Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science. 2002;298(5599):1790-3.
15. Wacker M, Feldman MF, Callewaert N, Kowarik M, Clarke BR, Pohl NL, et al. Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc Natl Acad Sci USA. 2006;103(18):7088-93.
16. Kowarik M, Young NM, Numao S, Schulz BL, Hug I, Callewaert N, et al. Definition of the bacterial N-glycosylation site consensus sequence. EMBO Journal. 2006;25(9):1957-66.
17. Cuccui J, Thomas RM, Moule MG, D'Elia RV, Laws TR, Mills DC, et al. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. Open Biol. 2013;3(5):130002.
18. Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thöny-Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact. 2010;9:61.
19. Iwashkiw JA, Fentabil MA, Faridmoayer A, Mills DC, Peppler M, Czibener C, et al. Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis. Microb Cell Fact. 2012;11:13.
20. Wetter M, Kowarik M, Steffen M, Carranza P, Corradin G, Wacker M. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component. Glycoconj J. 2013;30(5):511-22.
21. Pandhal J, Woodruff LB, Jaffe S, Desai P, Ow SY, Noirel J, et al. Inverse metabolic engineering to improve Escherichia coli as an N-glycosylation host. Biotechnol Bioeng. 2013;110(9):2482-93.
22. Pandhal J, Desai P, Walpole C, Doroudi L, Malyshev D, Wright PC. Systematic metabolic engineering for improvement of glycosylation efficiency in Escherichia coli. Biochem Biophys Res Commun. 2012;419(3):472-6.
23. Pandhal J, Ow SY, Noirel J, Wright PC. Improving N-glycosylation efficiency in Escherichia coli using shotgun proteomics, metabolic network analysis, and selective reaction monitoring. Biotechnol Bioeng. 2011;108(4):902-12.
24. Choi JH, Keum KC, Lee SY. Production of recombinant proteins by high cell density culture of Escherichia coli. Chemical Engineering Science. 2006;61(3):876-85.
25. Lee SY. High cell-density culture of Escherichia coli. Trends Biotechnol. 1996;14(3):98-105.
26. Terra VS, Mills DC, Yates LE, Abouelhadid S, Cuccui J, Wren BW. Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design. J Med Microbiol. 2012;61:919-26.
27. Lindberg AA, Karnell A, Weintraub A. The lipopolysaccharide of Shigella bacteria as a virulence factor. Rev Infect Dis. 1991;13 Suppl 4:S279-84.
28. Wagner A, Stiegler G, Vorauer-Uhl K, Katinger H, Quendler H, Hinz A, et al. One step membrane incorporation of viral antigens as a vaccine candidate against HIV. J Liposome Res. 2007;17:139-54.
29. Wagner S, Bader ML, Drew D, de Gier JW. Rationalizing membrane protein overexpression. Trends Biotechnol. 2006;24:364-71.
30. Purvis JE, Yomano LP, Ingram LO. Enhanced trehalose production improves growth of Escherichia coli under osmotic stress. Appl Environ Microbiol. 2005;71(7):3761-9.
31. Joseph TC, Rajan LA, Thampuran N, James R. Functional characterization of trehalose biosynthesis genes from E. coli: an osmolyte involved in stress tolerance. Mol Biotechnol. 2010;46(1):20-5.
32. Strom AR, Kaasen I. Trehalose metabolism in Escherichia coli: stress protection and stress regulation of gene expression. Mol Microbiol. 1993;8(2):205-10.
33. Gerber S, Lizak C, Michaud G, Bucher M, Darbre T, Aebi M, et al. Mechanism of bacterial oligosaccharyltransferase: in vitro quantification of sequon binding and catalysis. J Biol Chem. 2013;288(13):8849-61.
34. Sharma CB, Lehle L, Tanner W. N-Glycosylation of yeast proteins. Characterization of the solubilized oligosaccharyl transferase. Eur J Biochem. 1981;116(1):101-8.
35. Lizak C, Gerber S, Numao S, Aebi M, Locher KP. X-ray structure of a bacterial oligosaccharyltransferase. Nature. 2011;474(7351):350-5.
36. Jeong KJ, Lee SY. High-level production of human leptin by fed-batch cultivation of recombinant Escherichia coli and its purification. Appl Environ Microbiol. 1999;65(7):3027-32.
37. Chen MM, Glover KJ, Imperiali B. From peptide to protein: comparative analysis of the substrate specificity of N-linked glycosylation in C. jejuni. Biochemistry. 2007;46(18):5579-85.
38. Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA. 2005;102(8):3016-21.
39. Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, et al. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis. 2014;209(10):1551-61.
40. Dmitriev BA, Knirel YA, Kochetkov NK, Hofman IL. Somatic antigens of Shigella - structural investigation on o-specific polysaccharide chain of Shigella dysenteriae type-1 lipopolysaccharide. Eur J Biochem. 1976;66(3):559-66.
41. Lvov VL, Shashkov AS, Dmitriev BA, Kochetkov NK, Jann B, Jann K. Structural studies of the o-specific side-chain of the lipopolysaccharide from Escherichia coli o-7. Carbohydr Res. 1984;126(2):249-59.
42. Collins T, Azevedo-Silva J, da Costa A, Branca F, Machado R, Casal M. Batch production of a silk-elastin-like protein in E. coli BL21 (DE3): key parameters for optimisation. Microb Cell Fact. 2013;12:21.
43. Lecina M, Sarro E, Casablancas A, Godia F, Cairo JJ. IPTG limitation avoids metabolic burden and acetic acid accumulation in induced fed-batch cultures of Escherichia coli M15 under glucose limiting conditions. Biochem Eng J. 2013;70:78-83.
44. Pinsach J, de Mas C, Lopez-Santin J. Induction strategies in fed-batch cultures for recombinant protein in Escherichia coli: Application to rhamnulose 1-phosphate aldolase. Biochem Eng J. 2008;41(2):181-7.
45. Carneiro S, Ferreira EC, Rocha I. Metabolic responses to recombinant bioprocesses in Escherichia coli. J Biotechnol. 2013;164(3):396-408.
46. Hoffmann F, Rinas U. Stress induced by recombinant protein production in Escherichia coli. Adv Biochem Eng Biotechnol. 2004;89:73-92.
47. Neubauer P, Lin HY, Mathiszik B. Metabolic load of recombinant protein production: Inhibition of cellular capacities for glucose uptake and respiration after induction of a heterologous gene in Escherichia coli. Biotechnol Bioeng. 2003;83(1):53-64.
48. Bentley WE, Kompala DS. Optimal induction of protein-synthesis in recombinant bacterial cultures. Ann N Y Acad Sci. 1990;589:121-38.
49. Dalbey RE, Wang P, Kuhn A. Assembly of bacterial inner membrane proteins. Annu Rev Biochem. 2011;80:161-87.
50. Konopka JB. N-acetylglucosamine (GlcNAc) functions in cell signaling. Scientifica (Cairo) 2012;Article ID 489208.
51. Amer AO, Valvano MA. Conserved aspartic acids are essential for the enzymic activity of the WecA protein initiating the biosynthesis of O-specific lipopolysaccharide and enterobacterial common antigen in Escherichia coli. Microbiology. 2002;148(Pt 2):571-82.
52. Yao Z, Valvano MA. Genetic analysis of the O-specific lipopolysaccharide biosynthesis region (rfb) of Escherichia coli K-12W3110: identification of genes that confer group 6 specificity to Shigella flexneri serotypes Y and 4a. J Bacteriol. 1994;176(13):4133-43.
53. Dutka-Malen S, Mazodier P, Badet B. Molecular cloning and overexpression of the glucosamine synthetase gene from Escherichia coli. Biochimie. 1988;70(2):287-90.
54. Mengin-Lecreulx D, van Heijenoort J. Characterization of the essential gene glmM encoding phosphoglucosamine mutase in Escherichia coli. J Biol Chem. 1996;271(1):32-9.
55. Mengin-Lecreulx D, van Heijenoort J. Copurification of glucosamine-1-phosphate acetyltransferase and N-acetylglucosamine-1-phosphate uridyltransferase activities of Escherichia coli: characterization of the glmU gene product as a bifunctional enzyme catalyzing two subsequent steps in the pathway for UDP-N-acetylglucosamine synthesis. J Bacteriol. 1994;176(18):5788-95.
56. Milewski S. Glucosamine-6-phosphate synthase-the multi-facets enzyme. Biochim Biophys Acta. 2002;1597(2):173-92.
57. Rogers MJ, Ohgi T, Plumbridge J, Soll D. Nucleotide sequences of the Escherichia coli nagE and nagB genes: the structural genes for the N-acetylglucosamine transport protein of the bacterial phosphoenolpyruvate: sugar phosphotransferase system and for glucosamine-6-phosphate deaminase. Gene. 1988;62(2):197-207.
58. Sasai K, Ikeda Y, Fujii T, Tsuda T, Taniguchi N. UDP-GlcNAc concentration is an important factor in the biosynthesis of beta1,6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V. Glycobiology. 2002;12(2):119-27.
59. Al-Dabbagh B, Mengin-Lecreulx D, Bouhss A. Purification and characterization of the bacterial UDP-GlcNAc:undecaprenyl-phosphate GlcNAc-1-phosphate transferase WecA. J Bacteriol. 2008;190(21):7141-6.
60. Liu B, Knirel YA, Feng L, Perepelov AV, Senchenkova SN, Wang Q, et al. Structure and genetics of Shigella O antigens. FEMS Microbiol Rev. 2008;32(4):627-53.
61. Lehane AM, Korres H, Verma NK. Bacteriophage-encoded glucosyltransferase GtrII of Shigella flexneri: membrane topology and identification of critical residues. Biochem J. 2005;389(Pt 1):137-43.
62. Igura M, Maita N, Kamishikiryo J, Yamada M, Obita T, Maenaka K, et al. Structure-guided identification of a new catalytic motif of oligosaccharyltransferase. EMBO J. 2008;27(1):234-43.
63. Welply JK, Shenbagamurthi P, Lennarz WJ, Naider F. Substrate recognition by oligosaccharyltransferase. Studies on glycosylation of modified Asn-X-Thr/Ser tripeptides. J Biol Chem. 1983;258(19):11856-63.
64. Riesenberg D, Schulz V, Knorre WA, Pohl HD, Korz D, Sanders EA, et al. High cell density cultivation of Escherichia coli at controlled specific growth rate. J Biotechnol. 1991;20(1):17-27.
65. Dykxhoorn DM, St Pierre R, Linn T. A set of compatible tac promoter expression vectors. Gene. 1996;177(1-2):133-6.
66. Ihssen J, Kowarik M, Wiesli L, Reiss R, Wacker M, Thöny-Meyer L. Structural insights from random mutagenesis of Campylobacter jejuni oligosaccharyltransferase PglB. Bmc Biotechnol. 2012;12:67.